Rocket Pharmaceuticals (RCKT) Equity Ratio (2016 - 2025)
Historic Equity Ratio for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Q3 2025 value amounting to 0.85.
- Rocket Pharmaceuticals' Equity Ratio rose 174.77% to 0.85 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.85, marking a year-over-year increase of 174.77%. This contributed to the annual value of 0.88 for FY2024, which is 92.99% up from last year.
- Rocket Pharmaceuticals' Equity Ratio amounted to 0.85 in Q3 2025, which was up 174.77% from 0.84 recorded in Q2 2025.
- Rocket Pharmaceuticals' 5-year Equity Ratio high stood at 0.92 for Q3 2021, and its period low was 0.83 during Q1 2021.
- For the 5-year period, Rocket Pharmaceuticals' Equity Ratio averaged around 0.88, with its median value being 0.88 (2022).
- Per our database at Business Quant, Rocket Pharmaceuticals' Equity Ratio surged by 2706.17% in 2021 and then crashed by 730.67% in 2024.
- Rocket Pharmaceuticals' Equity Ratio (Quarter) stood at 0.91 in 2021, then fell by 3.0% to 0.89 in 2022, then decreased by 1.99% to 0.87 in 2023, then grew by 0.93% to 0.88 in 2024, then fell by 2.91% to 0.85 in 2025.
- Its Equity Ratio was 0.85 in Q3 2025, compared to 0.84 in Q2 2025 and 0.87 in Q1 2025.